
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx Inc has demonstrated robust financial performance with a 19% year-over-year revenue growth in 2024, bolstered by steady quarter-over-quarter increases in testing volume, which reached 45,500 in Q4, marking a 14% increase from the previous quarter. The company's effective growth strategies, including initiatives to enhance testing solutions for transplant centers and expand payer coverage, position it well for an anticipated 17% revenue growth in 2025, with a long-term target of achieving $500 million in revenue by 2027 alongside a 20% adjusted EBITDA. Additionally, CareDx's estimated market value has risen to $1.43 billion, reflecting positive market sentiment and potential for continued financial advancement.
Bears say
CareDx Inc faces several fundamental challenges that contribute to a negative outlook for its stock. The company's financial performance is at risk due to potential reimbursement issues for its testing services, particularly if rates are reduced or if CareDx fails to secure reimbursement altogether. Additionally, increasing competition in the diagnostics sector, along with the potential for tighter healthcare regulations and difficulties in integrating acquisitions, could further hinder the company's market position and financial results.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares